Sex Steroids Block the Initiation of Atherosclerosis

Frederick Naftolin1, Holly Mehr2, Ahmed Fadiel2

  • 1Department of Obstetrics and Gynecology, New York University, New York, NY, USA frederick.naftolin@nyumc.org.

Insights

Sex steroids prevent atherosclerosis by inducing sialylation of neural cell adhesion molecules (nCAM) on endothelial cells. This process blocks monocyte capture, a key early step in artery hardening and plaque formation.

Area of Science:

  • Cardiovascular Biology
  • Endocrinology
  • Cellular Biology

Background:

  • Atherosclerosis, or hardening of the arteries, is a leading cause of death.
  • It involves the accumulation of fat-laden macrophages forming vascular plaque.
  • Inflammation and monocyte recruitment to injured vessels initiate atherogenesis.

Purpose of the Study:

  • To investigate the role of sex steroids in preventing atherosclerosis.
  • To determine if sex steroid pretreatment inhibits monocyte capture by endothelial cells.
  • To explore the mechanism of sex steroid-induced inhibition of atherogenesis.

Main Methods:

  • In vitro study using human arterial endothelial cells.
  • Pretreatment with estradiol, testosterone, dehydroepiandrosterone, and dihydrotestosterone.
  • Assessed nCAM sialylation and monocyte capture using dose-response analysis.

Main Results:

  • Estradiol-induced nCAM sialylases are present in vascular endothelial cells.
  • Sex steroid pretreatment (estradiol, testosterone, DHEA, DHT) increased endothelial cell sialylation.
  • Sialylation dose-dependently reduced monocyte capture by endothelial cells.

Conclusions:

  • Sex steroids are protective against atherosclerosis.
  • Sex steroid-induced nCAM sialylation blocks the initial step of atherogenesis.
  • This mechanism may be crucial for hormonal prevention of atherosclerosis.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
556
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.8K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Inflammation01:38

Inflammation

Overview
63.5K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K